Sugar-lipid MacCer promotes sudden-triggering by regulating the Wg signaling pathway.
Time of Update: 2020-08-07
synapses. further genetic analysis combined with liposome-specific antibody staining found that GSL glycolic-glucose ceramide (MacCer) promotes synaptic growth. GSL is assembled into a fat raft with sterols on biofilms. immunostaining
Grace launches new high-performance water-based wood coating consumer that optimizes paint
Time of Update: 2020-07-12
, Grace, a global leader in specialty silica, recently introduced two new high-quality extinction agents designed for environmentally friendly water-based wood coating applications: SYLOID® AQ 800 and SYLOID® AQ 880 silicon dioxide.
Grace expands European plant LUDOX®️ silicone sol production doubles
Time of Update: 2020-07-11
, June 23, 2020, Grace Corporation of the United States, a global leader in specialty silica, announced the opening of its new siliconsol plant, which is located 82 square meters and equipped with state-of-the-art processes
No need to consider the approval of Bristol Myers Squibb inhibitor for PD-L1 expression
Time of Update: 2020-06-19
From: immediate medical news Bristol Myers Squibb (BMS) recently announced that its heavyweight PD-1 inhibitor, opdivo (nivolumab), has been approved by the US FDA to treat advanced, recurrent or metastatic esophageal squamous cell carcinoma
Anti CD19 car-t cell therapy! Bristol Myers Squibb LISO cel has been given priority by the US FDA in the treatment of relapsed / refractory large B-cell lymphoma
Time of Update: 2020-02-15
February 15, 2020 / BIOON / -- Bristol Myers Squibb (BMS) recently announced that the US Food and Drug Administration (FDA) has accepted lisocabtargene Maraleucel (Lisa cel
Bristol Myers Squibb car-t therapy qualified for priority review
Time of Update: 2020-02-14
Today, Bristol Myers Squibb (BMS) announced that the U.S
FDA has accepted its car-t therapy lisocabatagene targeting CD19 antigen Maraleucel (LISO CEL) is a biologicals
Bristol Myers Squibb launches new biomedical innovations to improve the lives of patients with inflammatory diseases
Time of Update: 2020-02-05
Today, Bristol Myers Squibb (BMS) and biomotiv jointly announced the launch of anteros pharmaceuticals, which focuses on the development of drugs to treat fibrosis and other inflammatory diseases.
Immune checkpoint + microbiome! Bristol Myers Squibb and Vedanta launched the first human study
Time of Update: 2019-12-29
December 29, 2019 news / BIOON / -- Vedanta Biosciences is a clinical stage microbiome company, focusing on the development of a new type of therapy based on a reasonably designed
The first combination therapy without chemotherapy for follicular lymphoma! Bristol Myers Squibb
Time of Update: 2019-12-23
December 23, 2019 / bioin / - Bristol Myers Squibb (BMS) recently announced that the European Commission (EC) has approved a new indication of Revlimid (lenalidomide, lenalidomide
Anti CD19 car-t cell therapy! Bristol Myers Squibb LISO cel outpatient treatment R / R NHL showed high remission rate (80%) and good safety!
Time of Update: 2019-12-12
December 12, 2019 / BIOON / -- the 61st annual meeting of the American Society of Hematology (ash2019) was recently held in Orlando, Florida, USA
At this meeting, BMS
Anti CD19 car-t cell therapy! Bristol Myers Squibb LISO cel in the treatment of relapsed / refractory large B cell NHL total remission rate of 100%!
Time of Update: 2019-12-11
These preliminary results show that LISO cel as a second-line therapy has good efficacy and safety in patients with aggressive, relapsed or refractory large B-cell non-Hodgkin's lymphoma who are not eligible for hematopoietic stem cell transplantation.
Anti CD19 car-t cell therapy! Bristol Myers Squibb LISO cel in the treatment of high-risk relapse
Time of Update: 2019-12-10
December 10, 2019 / BIOON / -- the 61st annual meeting of the American Society of Hematology (ash2019) was recently held in Orlando, Florida, USA
At this meeting, BMS
Bristol Myers Squibb completes the acquisition of Xinji
Time of Update: 2019-11-21
Accelerate share buyback of Bristol Myers Squibb also announced that the company's board of directors has authorized the buyback of the company's common shares, with a buyback amount of $7 billion.
Immunotherapy for advanced liver cancer! Priority review of Bristol Myers Squibb oy portfolio in the US
Time of Update: 2019-11-13
On November 11, BMS announced that FDA has accepted a supplementary biological product license application (SBLA) submitted by BMS, and awarded the breakthrough drug qualification
Immunotherapy for liver cancer! Bristol Myers Squibb opdivo + yervoy combination entered
Time of Update: 2019-11-12
November 12, 2019 / BIOON / - tumor The US Food and Drug Administration (FDA) has accepted a supplementary biological product license application (SBLA) from opdivo (Chinese trade
Melanoma adjuvant treatment! The four week dose regimen (Q4w) of Bristol Myers Squibb opdivo has been recommended and approved in the European Union!
Time of Update: 2019-09-25
September 25, 2019 / BIOON / - Bristol Myers Squibb (BMS) recently announced that the European Drug Administration (EMA) human pharmaceutical products Committee (CHMP) has issued
Bristol Myers Squibb announces opdivo's cumulative five year survival rate
Time of Update: 2019-09-11
Bristol Myers Squibb (NYSE: BMY) today released the results of a three-stage, long-term clinical efficacy study and safety review of checkmate-017 and checkmate-057 in patients with previously treated advanced non-small cell lung cancer (NSCLC).
New drug for multiple myeloma! Bristol Myers Squibb / EPD EU approved the second 3-drug scheme of dupliciti!
Time of Update: 2019-08-28
August 28, 2019 / BIOON/ --BMS recently announced that the European Commission (EC) has approved the combination of immunostimulatory therapy (elotuzumab) with pomalidomide
New drug for multiple myeloma! Bristol Myers Squibb / ibuprofen immunostimulatory therapy (dupliciti) has been recommended and approved by CHMP
Time of Update: 2019-07-29
July 29, 2019 / BIOON/ --BMS recently announced that the European Drug Administration (EMA) human pharmaceutical products Committee (CHMP) has issued a positive review opinion
Colorectal cancer "target + immune" treatment will meet a major breakthrough! Bayer and Bristol
Time of Update: 2019-07-19
July 19, 2019 / BIOON / - Bayer, BMS and Ono jointly announced that three companies had signed a clinical cooperation agreement to evaluate the tumor of stivarga and PD-1